Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Renoprotective effects of empagliflozin in type 1 and type 2 models of diabetic nephropathy superimposed with hypertension
Jan M. Williams, Sydney Murphy, Wenjie Wu, et al.
GeroScience (2022) Vol. 44, Iss. 6, pp. 2845-2861
Open Access | Times Cited: 10

Showing 10 citing articles:

Recent Advances in Understanding Peripheral and Gut Immune Cell-Mediated Salt-Sensitive Hypertension and Nephropathy
Mohammad Saleem, Sepiso K. Masenga, Jeanne Ishimwe, et al.
Hypertension (2024) Vol. 81, Iss. 3, pp. 436-446
Closed Access | Times Cited: 9
A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans
Martin C. Michel, Eric Mayoux, Volker Vallon
Naunyn-Schmiedeberg s Archives of Pharmacology (2015) Vol. 388, Iss. 8, pp. 801-816
Open Access | Times Cited: 68
Concomitant inhibition of TLR-4 and SGLT2 by phloretin and empagliflozin prevents diabetes-associated ischemic acute kidney injury
Vishwadeep Shelke, Ajinath Kale, Neha Dagar, et al.
Food & Function (2023) Vol. 14, Iss. 11, pp. 5391-5403
Closed Access | Times Cited: 12
Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors—is hemodynamics the key point?
Blaire Lee, Niels‐Henrik Holstein‐Rathlou, Olga Sosnovtseva, et al.
AJP Cell Physiology (2023) Vol. 325, Iss. 1, pp. C243-C256
Closed Access | Times Cited: 9
A glycopolymersome strategy for ‘drug-free’ treatment of diabetic nephropathy
Jiamin Zhang, Tong Wu, Chang Li, et al.
Journal of Controlled Release (2024) Vol. 372, pp. 347-361
Closed Access | Times Cited: 3
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy
Aqsa Ashfaq, Myriam Meineck, Andrea Pautz, et al.
Pharmacology & Therapeutics (2023) Vol. 249, pp. 108503-108503
Closed Access | Times Cited: 6
Canagliflozin and irbesartan ameliorate renal fibrosis via the TGF-β1/Smad signaling pathway in Dahl salt-sensitive rats
Jianlong Zhai, Zhongli Wang, Tingting Zhang, et al.
Journal of International Medical Research (2023) Vol. 51, Iss. 10
Open Access | Times Cited: 1
Sex-dependent effects of Canagliflozin on kidney protection in mice with combined hypertension-type 1 diabetes
Mayra Trentin‐Sonoda, Véronique Cheff, Alex Gutsol, et al.
PLoS ONE (2023) Vol. 18, Iss. 12, pp. e0295284-e0295284
Open Access | Times Cited: 1
Empagliflozin alleviates diabetic nephropathy in albino rats through its antioxidative and anti-inflammatory action

Jordan Journal of Applied Science - Natural Science Series (2023) Vol. 17, Iss. 1
Open Access
Effects of canagliflozin and irbesartan on renal fibrosis in Dahl salt-sensitive rats
Jianlong Zhai, Zhongli Wang, Tingting Zhang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top